Enhancement by sodium orthovanadate of the formation and mineralization of bone nodules by chick osteoblasts in vitro.
Orthovanadate is a known inhibitor of phosphotyrosyl protein phosphatase and is reported to stimulate osteogenic cell proliferation and differentiation when administered during the logarithmic growth phase and to potentiate the mitogenic effects of several growth factors. There is little information concerning the effects of orthovanadate on bone matrix deposition and mineralization, although there is some evidence that it increases collagen synthesis by osteogenic cells. To test the effects of orthovanadate on bone nodule formation and mineralization, osteogenic cells were exposed to 5-50 microM orthovanadate or 10(-7) M insulin-like growth factor-1 for 3, 7, and 21 days after plating. Exposure to orthovanadate produced differential effects on cellular proliferation and alkaline phosphatase activity following completion of the logarithmic growth phase, and on resultant bone nodule formation and mineralization by these populations. The effects of orthovanadate on osteogenic cultures were concentration dependent: 5 microM concentrations produced by a relatively large quantity of poorly mineralized matrix, while 30-50 microM concentrations produced a smaller quantity of heavily mineralized matrix. Thus, orthovanadate could possibly be used as a growth factor for bone, if administered at the critical dosage at the proper stage of the life cycle of the osteoblast.
Johnson
R B
RB
Department of Periodontics, University of Mississippi, School of Dentistry, Jackson, USA.
Henderson
J S
JS
D000469:Alkaline Phosphatase; D000704:Analysis of Variance; D000818:Animals; D001857:Bone Matrix / Q000187:drug effects / Q000378:metabolism; D002113:Calcification, Physiologic / Q000187:drug effects; D002454:Cell Differentiation / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D002642:Chick Embryo; D004305:Dose-Response Relationship, Drug; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D010006:Osteoblasts / Q000187:drug effects* / Q000201:enzymology; D010012:Osteogenesis / Q000187:drug effects*; D018709:Statistics, Nonparametric; D013997:Time Factors; D014638:Vanadates / Q000008:administration & dosage / Q000494:pharmacology*
D014638:Vanadates; D007334:Insulin-Like Growth Factor I; D000469:Alkaline Phosphatase